Arda Ural

EY Americas life sciences sector leader and dealmaking expert, providing analysis on biopharma M&A trends, therapeutic area dynamics, and the impact of AI and global policy on industry dealmaking.

Best podcasts with Arda Ural

Ranked by the Snipd community

Dec 5, 2025 • 26min

The biopharma dealmaking landscape and what to expect in 2026

Arda Ural, EY's Americas life sciences leader and dealmaking expert, shares insights on the evolving biopharma landscape. He discusses the shift towards larger, low-risk acquisitions post-pandemic and highlights revitalized therapeutic areas driving deals, such as oncology and neurology. Ural addresses the Federal Trade Commission's scrutiny of mergers and the long-term impacts of NIH funding cuts on innovation. He also emphasizes the rapid rise of AI in biopharma R&D and China's emergence as an innovation powerhouse, shaping future dealmaking.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app